GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GSK received a Complete Response letter from the FDA for the sNDA for Avodart for reducing the risk of prostate cancer in men.
Read the full article15y agoen
You might also wanna read
OpenAI No. 2 Executive Fidji Simo Steps Down from Full-Time Role to Focus on Health Recovery
Variety·6h ago
Why ambulance rides in the US are so expensive: The broken economics of emergency medical transport
davidoks.blog·8h agoModerna's mResvia gets shot in the arm from EU contract
pharmaphorum·8h ago
Australia news live: Hanson defends UK ‘fact-finding’ trip; Qantas tops airline punctuality table
The Guardian·8h ago
STAT+: FDA finalists under review
STAT·15h ago
STAT+: Prime wins Beam arbitration, clearing path to clinic
STAT·16h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.